ESPNIC Children’s Intensive Care Textbook

ESPNIC Children’s Intensive Care Textbook

Kaup valmöguleikar

Þessi kennslubók fjallar um grundvallaratriði gjörgæslu barna frá evrópsku sjónarhorni. Hún er gagnleg leiðarvísir fyrir byrjendur, heilbrigðisstarfsfólk á gjörgæsludeildum og aðrar tengdar fagstéttir. Fjallað er um hlutverk gjörgæsludeilda á nútímalegum barnasjúkrahúsum, sérstakar klínískar aðstæður, viðurkennda starfshætti, aðferðir og viðeigandi meðferðir við mismunandi sjúkdómsástandi.

Sérstakur hluti bókarinnar fjallar um einstök líffæri og líffærakerfi, þar á meðal lungu, hjarta og blóðrás, nýru og nýrnauppbótarmeðferð, meltingarveg, heila, lifur og bris. Einnig er fjallað um bólguviðbrögð, ónæmiskerfið og sýklasótt, auk efnaskipta og efnaskiptasjúkdóma á gjörgæsludeild. Aðrir hlutar fjalla um gjörgæslu vegna hjartasjúkdóma og taugasjúkdóma. Bókin er ritstýrð og skrifuð af virtum sérfræðingum á þessu sviði. Kaflarnir eru settir fram með áherslu á nám og innihalda hagnýt dæmi, lykilatriði og skýr lokaorð, svo lesendur geti tileinkað sér efnið á auðveldan hátt og nýtt þekkinguna við klínískar aðstæður.

Nánar um bókina

Útgefandi
Springer Nature
ISBN
9783031647628
Print ISBN
9783031647611
Format
ePub
Útgáfa
0
Höfundar
Tungumál
English
Útgefið
2025-07-01
Prent takmörkun á líftíma
100
Prent takmörkun
2
Afritunar takmörkun
2

Kaflar

  • ESPNIC Children’s Intensive Care Textbook
  • Introduction
  • Contents
  • Contributors
  • I: Introduction
  • 1. Paediatric and Neonatal Intensive Care: Quo Vadis
  • 1.1 Introduction
  • 1.2 Cell-Based and Genetic Therapy
  • 1.3 Extracorporeal Support Devices
  • 1.4 Brain and Critical Illness
  • 1.5 Evidence Base Pharmacotherapy
  • 1.6 Long-Term Outcome
  • 1.7 Reflection
  • II: Why Do Children Need Critical Care
  • 2. Elective Admission to Critical Care
  • 2.1 Introduction
  • Case Study 1
  • Questions to Consider
  • Case Study 2
  • 2.2 Preparing the Child and Family Psychologically for an Elective Critical Care Unit (CCU) Admission
  • 2.3 Optimising the Physical Condition of the Child Prior to Surgery and Critical Care Unit Admission
  • III: Mortality Predictions and Severity of Illness Scores
  • 3. Severity of Illness and Organ Dysfunction Scoring in Pediatric Intensive Care Units: Developments in 2020
  • 3.1 Introduction
  • 3.1.1 Which Severity Scores Are Available for Use in Pediatric Intensive Care?
  • 3.1.2 What Organ Dysfunction Scores Are Currently Available?
  • 3.1.3 Probabilities of Death
  • 3.1.4 ICU Score Quality
  • 3.2 Performance and Adaptation of the Scores
  • 3.2.1 Score Performance: What Is Evaluated and How to Measure Performance?
  • 3.2.2 Adaptation of the Scores
  • 3.2.3 Why Use a Severity or Organ Dysfunction Score in Pediatric Intensive Care?
  • 3.2.3.1 Objective Assessment of the Severity and Organ Dysfunctions for Each Patient
  • 3.2.3.2 Use in Studies
  • Description of Tools Used
  • Study Inclusion Criteria
  • Comparing Illness Severity in Randomized Trials
  • 3.3 Evaluation of the Recruitment and Performance of a Service
  • 3.4 Future Considerations
  • 3.4.1 Health Quality of Life Scores
  • 3.4.2 Evaluation of Practices in Pediatric Intensive Care Units
  • 3.5 Conclusion
  • 4. Paediatric Early Warning Scores
  • 4.1 Introduction
  • 4.2 What Is a Paediatric Early Warning Score?
  • 4.3 Why Might We Need a PEWS?
  • 4.4 Types of PEWS
  • 4.4.1 Score-Based System
  • 4.4.2 Trigger-Based Systems
  • 4.4.3 Which Type of PEWS Is Best?
  • 4.5 What Is the Evidence for PEWS?
  • 4.5.1 A Landmark Study: The EPOCH Trial
  • 4.6 How Might We Assess the Quality of a PEWS?
  • 4.7 PEWS as Part of a Wider System Response
  • 4.8 What’s the Future for PEWS?
  • 4.9 Practical Tips for Maximising the Effectiveness of PEWS
  • IV: ICU Structure
  • 5. ICU: Gas, Humidity, Power and Airflow
  • 5.1 Introduction
  • 5.2 Single Family Rooms Versus Open-Bay Units
  • 5.3 NICU/PICU Location Within the Hospital
  • 5.4 Support Areas
  • 5.5 Specialized Procedure Spaces
  • 5.6 Noise, Light, Temperature and Humidity
  • 5.7 Electrical, Gas Supply and Mechanical Needs
  • 5.8 Handwashing Facilities
  • 5.9 Airborne Infection Isolation Room
  • 5.10 Access to Nature and Other Positive Distraction
  • 5.11 Ceiling Finishes, Wall Surface and Floor Surface
  • 6. Basic Patient Safety and Quality in PICU
  • 6.1 Introduction
  • 6.2 Culture
  • 6.3 Data, Data, Data!
  • 7. Handover from Operating Theatre
  • 7.1 Why Are Effective Handovers So Important for the Patient’s Safety?
  • 7.2 Team Performance and Commons Errors
  • 7.2.1 Communication Team Performance
  • 7.2.2 Inputs
  • 7.2.3 Processes
  • 7.2.4 Outcomes
  • 7.2.5 Mains Parameters of Ineffective Handover
  • 7.3 How to Manage an Effective Handover?
  • 8. Infection Prevention and Control in the Paediatric Intensive Care Unit
  • 8.1 Introduction
  • 8.2 Prevention of Infection in PICU
  • 8.3 Modes of Transmission of Infectious Agents
  • 8.4 Prevention for Transmission of Infectious Agents
  • 8.4.1 Standard Infection Control Precautions (SICPs)
  • 8.4.1.1 Hand Hygiene
  • 8.4.1.2 Personal Protective Equipment (PPE)
  • 8.4.1.3 Prevention of Invasive Device-Associated Infections
  • 8.4.2 Care Bundles
  • 8.4.2.1 VAP Care Bundle in Children
  • 8.4.2.2 Central Line Care Bundle (Insertion and Care and Maintenance)
  • 8.5 Aseptic Technique
  • 8.6 Aseptic Non-Touch Technique (ANTT)
  • 8.7 Environment Build, Materials and Equipment for IPC in PICU
  • Case Study: IPC for SARS CoV-2 in PICU
  • 8.8 Cleaning Standards
  • 9. Information Technology in PICU
  • 9.1 Introduction
  • 9.2 Electronic Health Records
  • 9.2.1 Clinical Documentation
  • 9.2.2 Electronic Charting
  • 9.3 Computerised Physician Order Entry (CPOE) Systems
  • 9.4 Clinical Decision Support Systems (CDSS)
  • 9.5 Automated Alerting Systems and Early Warning Scores
  • 9.6 Telemedicine
  • 9.7 Machine Learning, Big Data and Artificial Intelligence
  • 9.8 Human–Technology Interface
  • 9.9 Conclusion
  • V: The Lung and Mechanical Ventilation in ICU
  • 10. Basic Respiratory Physiology
  • 10.1 Foetal and Postnatal Development
  • 10.2 Surfactant and Foetal Lung Fluid
  • 10.3 Transition from Foetal to Postnatal Cardiorespiratory Function
  • 10.4 Postnatal Development
  • 10.5 How Structure Serves Function
  • 10.6 Ventilation and Lung Volumes
  • 10.7 Diffusion
  • 10.8 Pulmonary Perfusion
  • 10.9 Ventilation–Perfusion Relationships
  • 10.10 Mechanics of Breathing
  • 10.11 Control of Respiration
  • 10.12 Ventilator Waveform Monitoring
  • Summary
  • Take-Home Messages
  • 11. Basics of Mechanical Ventilation
  • 11.1 The Mechanical Behaviour of the Respiratory System (in the Ventilated Patient)
  • 12. Oxygen Therapy and Acute Noninvasive Ventilation in Children
  • 12.1 Noninvasive Ventilation
  • 12.1.1 Introduction
  • 12.1.2 Indications
  • 12.1.2.1 Long-Term Ventilatory Support
  • 12.1.2.2 Short-Term Ventilatory Support
  • Hypoxemic Respiratory Failure (Type I)
  • Hypercapnic Respiratory Failure (Type II)
  • 12.1.3 Contraindications
  • 12.1.4 Equipment
  • 12.1.4.1 Types of NIV Ventilators
  • 12.1.4.2 Circuits (◘ Fig. 12.1)
  • 12.1.4.3 Humidification
  • 12.1.4.4 Exhalation Port (◘ Fig. 12.2)
  • 12.1.4.5 Anti-Asphyxia Valve (◘ Fig. 12.3)
  • 12.1.4.6 Interfaces (◘ Table 12.3)
  • 12.1.5 Ventilation Modes
  • 12.1.5.1 Volume-Controlled Modes
  • 12.1.5.2 Pressure-Controlled Modes (◘ Table 12.4)
  • 12.1.5.3 Initial Settings
  • 12.1.6 Installation
  • 12.1.7 Analysis
  • 12.1.7.1 Efficiency
  • 12.1.7.2 Tolerance
  • 12.1.8 Next Steps
  • 12.2 HFNC
  • 12.2.1 Introduction
  • 12.2.2 Mechanism of Action
  • 12.2.2.1 Gas Mixture Conditioning
  • 12.2.2.2 High Flow
  • 12.2.2.3 Generated Pressures
  • 12.2.3 Side Effects and Monitoring
  • 12.2.4 HFNC Initiation in Practice (◘ Fig. 12.5)
  • 12.2.4.1 Where to Initiate HFNC
  • 12.2.4.2 Cannula
  • 12.2.4.3 Generator
  • 12.2.4.4 Settings (◘ Table 12.7)
  • 12.2.5 Indications for HFNC
  • 12.2.5.1 Acute Viral Bronchiolitis
  • 12.2.5.2 Withdrawal of Invasive Ventilation
  • 12.2.5.3 Asthma
  • 12.2.5.4 ARDS
  • 12.2.5.5 Preoxygenation and Intubation
  • 12.2.6 Conclusion
  • 13. Paediatric Acute Respiratory Distress Syndrome (pARDS)
  • 13.1 Introduction
  • 13.2 Definition of Paediatric ARDS (pARDS) (◘ Table 13.1)
  • 13.3 Epidemiology
  • 13.4 Pathophysiology
  • 13.5 Monitoring
  • 13.5.1 General
  • 13.5.2 Respiratory System Mechanics
  • 13.5.3 Oxygenation and CO2 Monitoring
  • 13.5.4 Chest Imaging
  • 13.5.5 Hemodynamic Monitoring
  • 13.6 Treatment
  • 13.6.1 Non-Invasive Respiratory Support (NRS)
  • 13.6.1.1 High Flow Nasal Cannula (HFNC)
  • 13.6.1.2 Non-Invasive Ventilation (NIV): Continuous Positive Airway Pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP)
  • 13.6.1.3 NRS in Resource-Limited Settings (RLS)
  • 13.6.2 Invasive Mechanical Ventilation (IMV)
  • 13.6.2.1 VT
  • 13.6.2.2 Pressures
  • 13.6.2.3 PEEP
  • 13.6.2.4 Lung-Protective Ventilation (LPV) Bundles
  • 13.6.2.5 Oxygenation Target
  • 13.6.2.6 Ventilation Target
  • 13.6.2.7 Mode of Ventilation
  • 13.6.2.8 Recruitment Manoeuvres (RMs)
  • 13.6.3 Ancillary Treatments [16, 17]
  • 13.6.3.1 Prone Positioning
  • 13.6.3.2 Inhaled Nitric Oxide (iNO)
  • 13.6.3.3 Surfactant
  • 13.6.3.4 Corticosteroids
  • 13.6.3.5 Neuromuscular Blockade (NMB)
  • 13.6.4 Other Ancillary Treatments [17]
  • 13.6.4.1 Fluid Management
  • 13.6.4.2 Nutrition
  • 13.6.4.3 Transfusion
  • 13.7 ECMO
  • 13.7.1 Indications/Initiation
  • 13.7.2 Ventilation Management
  • 13.8 Outcomes
  • 14. Physiology of Modes of Ventilation in Severe Acute Lung Injury (ALI)
  • 14.1 Introduction
  • 14.2 Taxonomy of Mechanical Ventilation
  • 14.3 Conventional Mechanical Ventilation Approaches During Acute Lung Injury
  • 14.4 High-Frequency Oscillatory Ventilation
  • 14.4.1 What Is HFOV?
  • 14.4.2 Clinical Evidence in Children
  • 14.4.3 Clinical Evidence in Adults
  • 14.4.4 Indications for and Timing of HFOV
  • 14.4.5 Lung Volume Optimization Manoeuvres
  • 14.4.6 Achieving the Lowest Stroke Volume
  • 14.4.7 HFOV Titration Weaning
  • 14.5 Airway Pressure Release Ventilation
  • 14.5.1 Description of APRV
  • 14.5.2 Physiologic Benefits
  • 14.5.3 Clinical Evidence in Children
  • 14.6 Liquid Ventilation
  • 14.7 Conclusions
  • 15. Paediatric Ventilator Liberation
  • 15.1 Introduction
  • 15.2 Operational Definitions: A Common Language
  • 15.2.1 Respiratory Support
  • 15.2.2 Liberation from Invasive MV
  • 15.2.3 Assessment for Liberation from Invasive MV
  • 15.2.4 Post-extubation NRS
  • 15.3 The Liberation Process
  • 15.3.1 Gradual Adjustment of Respiratory Support
  • 15.3.2 Protocol-Based Screening
  • 15.3.2.1 Clinical Criteria
  • 15.3.2.2 Respiratory Support
  • 15.3.3 Extubation Readiness
  • 15.3.3.1 Anticipate and Prevent Post-extubation UAO
  • 15.3.3.2 Airway Protection
  • 15.3.3.3 Anticipate Post-extubation Non-invasive Respiratory Support
  • 15.3.4 Spontaneous Breathing Test (SBT)
  • 16. Ventilation of the Infant
  • 16.1 Introduction
  • 16.2 Indications
  • 16.3 Ancillary Therapies During Infant Ventilation
  • 16.4 Monitoring During Infant Ventilation
  • VI: Fluids and Hemodynamics
  • 17. Hemodynamic Physiology
  • 17.1 Introduction
  • Case Study 1
  • 17.2 The Heart
  • 17.2.1 Preload
  • 17.2.2 Afterload
  • 17.2.3 Contractility
  • 17.2.4 Other Aspects
  • 17.3 Venous Return
  • 17.4 Arterial Pressure
  • 17.5 Venous Pressure
  • Case Study 2
  • 17.6 Oxygen Transport
  • 17.7 Microcirculation
  • 17.8 Specific Aspects of Young Children
  • Summary
  • 18. Hemodynamic Monitoring in the PICU
  • 18.1 Introduction
  • 18.2 Cardiovascular Instability Is Common in Critically Ill Children
  • 18.3 Basic Bedside Assessment
  • 18.4 Blood Pressure
  • 18.4.1 Central Venous Pressure (CVP)
  • 18.4.2 Central Venous Oxygen Saturation Measurement
  • 18.4.3 Cardiac Output Monitoring and Transpulmonary Indicator Dilution
  • 18.4.4 Pulmonary Artery Pressure
  • 18.4.5 Serum Lactate Measurement
  • 18.4.6 Near-Infrared Spectroscopy
  • 18.4.7 Microcirculation
  • 18.4.8 Echocardiography/Ultrasonography
  • 18.4.9 Prediction of Volume Resuscitation and Fluid Responsiveness
  • 19. Fluids on PICU (Paediatric Intensive Care Unit)
  • 19.1 Introduction
  • 19.2 History of Intravenous Fluids
  • 19.3 The Body Fluid Compartments
  • 19.3.1 What Is the Total Body Water Content of a Child?
  • 19.3.2 Fluid Input and Output
  • 19.3.2.1 Definitions
  • 19.3.3 Isotonic, Hypotonic, and Hypertonic Fluids
  • 19.4 Regulation of Extracellular Fluid Osmolarity and Sodium
  • 19.5 Intravenous Fluids Commonly Used on PICU
  • 19.5.1 Crystalloid
  • 19.5.2 Colloid
  • 19.5.2.1 5% Human Albumin Solution
  • 19.5.2.2 Gelatin-Based Solutions
  • 19.5.2.3 Starch-Based Solutions
  • 19.5.3 What Happens During Rapid Infusion 10–20 mL/kg 0.9% Saline into a Patient?
  • 19.5.3.1 Distribution
  • 19.5.3.2 Changes to Plasma Oncotic Pressure
  • 19.5.3.3 Excretion
  • 19.5.3.4 Acid–Base Effects
  • 19.5.3.5 Possible Deleterious Effects
  • 19.5.3.6 Rationale for Intravenous Fluids
  • 19.6 Fluid Resuscitation in Shock
  • 19.6.1 What Is a Fluid Bolus? How Much to Give?
  • 19.6.2 Haemodynamic Targets of Fluid Bolus Therapy
  • 19.6.3 What Fluid to Use for Acute Resuscitation?
  • 19.6.4 What Are the Potential Harms of Fluid Bolus Therapy?
  • 19.7 Intravenous Fluid Maintenance in PICU
  • 19.7.1 Paediatric Fluid Requirements
  • 19.7.2 Neonatal Fluid Requirements
  • 19.7.3 Dealing with Fluid Losses
  • 19.7.4 What Maintenance Fluid to Use?
  • 19.7.5 Glucose Requirements
  • 19.7.6 What Maintenance Fluid to Use Postoperatively?
  • 19.7.7 How Is Fluid Balance Assessed?
  • 19.8 Phases of Fluid Therapy: The “ROSE” Concept
  • 19.8.1 What Is Fluid Overload and Is It Important?
  • 19.8.2 How Do I Deresuscitate My Patient?
  • 20. Vasoactive Agents
  • 20.1 Introduction
  • 20.2 What Are Inotropes?
  • 20.3 Some Terms
  • 20.4 Cardiovascular System
  • 20.4.1 Recognition and Assessment of Shock
  • 20.4.2 Targets
  • 20.4.3 How Do Inotropes Work
  • 20.4.3.1 Polymorphisms
  • 20.4.3.2 Receptor Downregulation
  • 20.4.4 Physiologic Mechanisms of Vasoconstriction
  • 20.5 Endogenous Inotropes and Vasoactive Agents: Sympathomimetic Amines
  • 20.5.1 Adrenaline
  • 20.5.2 Noradrenaline
  • 20.5.3 Vasopressin
  • 20.5.4 Dopamine
  • 20.6 Exogenous Inotropes and Vasoactive Agents
  • 20.6.1 Dobutamine
  • 20.6.2 Phenylephrine
  • 20.6.3 Phosphodiesterase Inhibitors
  • 20.6.4 Levosimendan
  • 20.7 Selection of Inotropic and Vasoactive Agents in Shock
  • 20.7.1 Septic Shock
  • 20.7.2 Cardiogenic Shock
  • 20.7.3 Neurogenic Shock
  • 20.8 Failure of Shock Reversal
  • 20.9 Conclusion
  • VII: Specific Organ System Failure
  • 21. The Lung
  • 21.1 Introduction
  • 21.2 Basics of Respiratory Physiology and Mechanics in the Neonate and the Growing Child
  • 21.3 Gas Exchange and Its Measures
  • 21.4 Respiratory Physiology, Mechanics and Gas Exchange Disturbances in Disease
  • 21.5 Cardiopulmonary Interactions
  • 22. Acute Kidney Injury in the PICU
  • 22.1 Introduction
  • 22.2 pAKI Definition
  • 22.3 Epidemiology
  • Box 22.1: Most Common AKI-Inducing Nephrotoxins
  • 22.4 Specific Aspects of pAKI Diagnosis
  • 22.5 Prevention
  • 22.6 Pharmacological Treatment
  • Box 22.2: Fluid Overload
  • 22.7 Follow-Up of Patients Surviving AKI
  • 23. The Gut
  • 23.1 Introduction
  • 23.2 The Gut: A Key Organ of Nutrition Physiology
  • 23.3 Gut Dysfunction in Critically Ill Children
  • 23.4 Main Symptoms of GI Dysfunction in Critically Ill Children: Prevalence, Causes, Prevention and Treatments
  • 23.5 Enteral Feeding Intolerance as a Result of GI Dysfunction
  • 23.6 Gut Damages in Case of Critical Illness
  • 23.7 Children with History of Intestinal Condition
  • 23.8 The Gut Microbiota
  • 23.8.1 The Role of Gut Microbiota
  • 23.8.2 Impact of Critical Illness on Gut Microbiota
  • 23.8.3 The Promising Effect of Nutrition and Probiotics in Critical Care
  • 24. Acute Liver Failure in PICU
  • 24.1 Introduction
  • 24.2 Definition of Paediatric Acute Liver Failure
  • 24.3 Aetiology
  • 24.4 Clinical Manifestation
  • 24.5 Hepatic Encephalopathy
  • 24.6 Management
  • 24.6.1 General Supportive Care
  • 24.6.2 Ventilation Strategies
  • 24.6.3 Neuroprotective Measures
  • 24.6.4 Ammonia Scavenging Strategy
  • 24.6.5 Hemodynamic Monitoring
  • 24.6.6 Fluid Requirement and Nutritional Support
  • 24.6.6.1 Role of N-Acetyl Cysteine in Management of Non-acetaminophen (Non-APAP) ALF
  • 24.6.6.2 Antibiotics in PALF
  • 24.6.7 Neuro-Critical Care Monitoring and Management of Intracranial Hypertension and Cerebral Oedema
  • 24.6.8 Indications
  • 24.7 Medical Management of ICP
  • 24.7.1 Hypertonic Saline
  • 24.7.2 Mannitol
  • 24.7.3 Thiopentone Sodium
  • 24.7.4 Therapeutic Hypothermia
  • 24.7.5 Hyperventilation
  • 24.7.6 Coagulation
  • 24.7.7 Acute Kidney Injury
  • 24.7.8 Indication for Starting CKRT in Patients with PALF
  • 24.7.9 Liver Support Devices
  • 24.7.10 Liver Transplant in ALF
  • 24.7.10.1 Models to Predict LT
  • 24.7.10.2 Post-Liver Transplant Management
  • 24.7.10.3 Long-Term Outcome
  • 25. Immunology in Paediatric Intensive Care
  • 25.1 Introduction
  • 25.2 Mucosal Immunity
  • 25.3 Inflammation and Innate Immunity
  • 25.3.1 Cell Autonomous Immunity
  • 25.3.2 Circulating Mediators of Infection
  • 25.4 Innate Immune Cells
  • 25.5 Adaptive Immunity
  • 25.5.1 T-Cell-Mediated Immunity
  • 25.5.2 B Cell-Mediated Immunity
  • 25.5.3 T Cell-Independent B Cell Immunity
  • 25.5.4 T Cell-Dependent B Cell Immunity
  • 25.6 Sepsis
  • 25.6.1 Personalised Immunomodulation in Sepsis?
  • 26. Metabolic Emergencies in the Paediatric Intensive Care Setting
  • 26.1 Introduction
  • 26.2 Clinical History and Examination
  • 26.3 Biochemical Investigations
  • 26.4 Management Principles
  • 26.5 Specific Scenarios
  • 26.5.1 Hyperammonaemia
  • 26.5.2 Metabolic Acidosis
  • 26.5.3 Glycaemic Control
  • 26.6 Peri-Mortem Considerations
  • Appendix: Other Key Drug Doses in the Intensive Care Setting
  • VIII: Cardiac Critical Care
  • 27. Basics in Cardiac Intensive Care
  • 27.1 Introduction
  • 27.2 Hemodynamic Monitoring
  • 27.2.1 Basic Hemodynamic Monitoring
  • 27.2.2 Assessment of Cardiac Output
  • 27.3 Preoperative Care of Pediatric Cardiac Surgical Patients
  • 27.3.1 Assessment of Patient Status and Predominant Physiology [1, 14]
  • 27.3.1.1 Defects with Left-to-Right Shunts
  • 27.3.1.2 Cyanotic Congenital Heart Defects
  • 27.3.1.3 Obstructive Congenital Heart Defects
  • 27.3.2 Other General Considerations
  • 27.4 Post-operative Care of Pediatric Cardiac Patients
  • 27.4.1 Preoperative and Intra-Operative Course Evaluation [6]
  • 27.4.2 General Principles of Post-Operative Care [6, 7, 14]
  • 27.4.3 Post-operative Complications
  • 27.4.4 Discharge from CICU
  • Case Study
  • 27.4.4.1 Proposed Evaluation
  • 28. Pre-operative Management of Neonates with Congenital Heart Disease
  • 28.1 Lesion-Specific Management
  • 28.2 Duct Dependent Systemic Lesions
  • 28.2.1 Coarctation of Aorta
  • 28.2.1.1 Pathophysiology
  • 28.2.1.2 Clinical Signs
  • 28.2.1.3 Pre-operative Management
  • 28.2.2 Critical Aortic Stenosis
  • 28.2.2.1 Pre-operative Management
  • 28.2.3 Hypoplastic Left Heart Syndrome (HLHS)
  • 28.2.3.1 Pathophysiology
  • 28.2.3.2 Main risk Factors for Postnatal Survival in HLHS Include
  • 28.2.3.3 Clinical Signs
  • 28.2.3.4 Pre-operative Management
  • 28.3 Duct Dependent Pulmonary Lesions
  • 28.3.1 Critical Pulmonary Stenosis
  • 28.3.1.1 Pathophysiology and Clinical Signs
  • 28.3.1.2 Pre-operative Management
  • 28.3.2 Pulmonary Atresia with Intact Ventricular Septum
  • 28.3.2.1 Pathophysiology and Clinical Signs
  • 28.3.2.2 Pre-operative Management
  • 28.3.3 Tetralogy of Fallot
  • 28.3.3.1 Pathophysiology and Clinical Signs
  • 28.3.3.2 Pre-operative Management
  • 28.4 Common Mixing Lesion
  • 28.4.1 Transposition of Great Arteries
  • 28.4.1.1 Pathophysiology
  • 28.4.1.2 Pre-operative Management
  • 28.4.2 Total Anomalous Pulmonary Venous Connection
  • 28.4.2.1 Pathophysiology and Clinical Signs
  • 29. Principles of Postoperative Management in the Paediatric Cardiac Intensive Care: Low Cardiac Output State (LCOS) and Lesion-Specific Management
  • 29.1 Introduction
  • 29.2 Low Cardiac Output State (LCOS)
  • 29.2.1 Definition
  • 29.2.2 Pathophysiology and Aetiology
  • 29.2.3 Diagnosis
  • 29.2.4 Prevention
  • 29.2.5 Treatment
  • 29.2.5.1 Optimising Preload
  • 29.2.5.2 Improving Myocardial Function
  • 29.2.5.3 Manipulating Afterload
  • Vasodilators
  • SVR Reduction
  • PVR Reduction
  • 29.2.6 Vasoconstrictors
  • 29.2.6.1 The Role of Positive Pressure Ventilation (PPV)
  • 29.2.6.2 The Role of Corticosteroids
  • 29.2.6.3 Mechanical Circulatory Support (MCS)
  • 29.3 Lesion-Specific Postoperative Management
  • 30. ECMO in Children with Cardiac Failure
  • 30.1 History of Cardiac ECMO
  • 30.2 Cardiac ECMO: Description and Indications
  • 30.3 Use and Strategy
  • 30.4 Contraindications
  • 30.5 Cannulation and ECMO Circuit
  • 30.5.1 Cannulation Technique
  • 30.5.2 Site of Cannulation
  • 30.5.3 Additional Cannulas
  • 30.5.4 Circuit
  • 30.6 ECMO Run: Management, Monitoring and Complications
  • 30.6.1 Goals and Principles of Cardiac ECMO
  • 30.6.2 Myocardial Stun
  • 30.6.3 Ventricular Decompression
  • 30.6.4 Residual Lesions
  • 30.6.5 Single Ventricle Physiology
  • 30.7 Cardiovascular Management and Monitoring
  • 30.7.1 Inotropes and Vasoactive Drugs
  • 30.7.2 Respiratory Management and Monitoring
  • 30.7.3 Anticoagulation
  • 30.7.4 Bleeding Management
  • 30.7.5 Blood Product Administration
  • 30.7.6 Renal Function
  • 30.7.7 Neurology and Sedation
  • 30.7.8 Infection
  • 30.8 Weaning and Decannulation
  • 30.9 Outcomes
  • 30.10 Future of Cardiac ECMO
  • 31. Extracorporeal Cardiopulmonary Resuscitation in Pediatric Age
  • 31.1 Introduction
  • 31.2 Definition of ECPR, Objective, and Indications
  • 31.3 Epidemiology of ECPR
  • 31.4 Outcomes
  • 31.4.1 Neurologic Outcomes
  • 31.4.2 Medium and Long-Term Outcomes
  • 31.5 ECPR Peculiarities in Specific Populations
  • 31.5.1 ECPR in Children with Cardiac Disease
  • 31.5.2 ECPR in Children with Noncardiac Disease
  • 31.5.3 Out-of-Hospital ECPR and ECPR for Deep Hypothermia
  • 31.6 Patient Selection and Factors Influencing EPCR Decision
  • 31.7 Team and Algorithm
  • 31.8 Cannulation Strategies and Equipment
  • 31.9 Post-ECPR Care
  • 32. Mechanical Circulatory Support in Paediatric Heart Failure
  • 32.1 Introduction
  • 32.2 Part 1: VAD Support
  • 32.2.1 Choice of Support Strategy: ECMO versus VAD
  • 32.2.2 Types of VAD
  • 32.2.3 Selecting the Right Type of VAD
  • 32.3 Part 2: Devices/Strategies LVAD, BiVAD and UVAD
  • 32.3.1 Strategies and Applications
  • 32.3.2 Right Ventricular Dysfunction
  • 32.3.3 Single-Ventricle Anatomy
  • 32.3.4 Recovery and Explant
  • 32.3.5 Destination Therapy
  • 32.4 Part 3: Anticoagulation
  • 32.4.1 Detection of Thrombosis
  • 32.5 Part 4: Patient Management and Outcomes
  • 32.5.1 Thrombotic and Bleeding Complications
  • 32.5.2 Optimising Haemodynamics
  • 32.5.3 Nursing and Multi-professional Care
  • 32.5.4 Outcomes
  • Case Studies
  • Case 1
  • Case 2
  • Case 3
  • Case 4
  • Summary
  • 32.6 Part 5: Palliative and Holistic Care
  • 32.6.1 Home Discharge
  • 33. Cardiac Arrhythmias: Diagnosis and Management for the Paediatric Intensivist
  • 33.1 Normal Cardiac Conduction
  • 33.1.1 Electrical Anatomy of the Heart
  • 33.1.2 ECG Recording in PICU
  • 33.2 Mechanism of Cardiac Arrhythmias
  • 33.3 Management
  • 33.3.1 General Considerations
  • 33.3.2 Antiarrhythmics
  • 33.3.3 Cardioversion and Defibrillation
  • 33.3.4 Temporary Cardiac Pacing
  • 33.4 Individual Arrhythmias
  • 33.4.1 Premature Atrial and Ventricular Complexes
  • 33.4.2 Tachyarrhythmias
  • 33.4.2.1 Junctional Ectopic Tachycardia (JET)
  • 33.4.2.2 Atrial Ectopic Tachycardia (AET)
  • 33.4.2.3 Supraventricular Tachycardia (SVT)
  • 33.4.2.4 Atrial Flutter and Intra-atrial Re-entry Tachycardia (IART)
  • 33.4.2.5 Ventricular Tachycardia (VT)
  • 33.4.3 Bradyarrhythmias
  • 33.4.3.1 Sinus Node Dysfunction
  • 33.4.3.2 Atrioventricular (AV) Block
  • 34. Outcomes of Paediatric Cardiac Intensive Care
  • 34.1 Introduction
  • 34.2 Outcome Measures
  • 34.3 Outcome Evaluation
  • 34.3.1 Registries and Multi-Institutional Collaborations
  • 34.3.2 Relationship Between Case Mix Complexity and Outcomes
  • 34.4 Solutions and Future Directions
  • IX: Neurocritical Care
  • 35. Paediatric Major Trauma in Context for the PICU Clinician
  • 35.1 What Is Major Trauma?
  • 35.1.1 Paediatric Major Trauma Networks
  • 35.2 Paediatric ‘Trauma Call’
  • 35.2.1 Pre-alerts
  • 35.2.2 Role of the PICU Doctor in a Trauma Call
  • 35.2.3 Team Preparation and ‘Crowd Control’
  • 35.2.4 Parents
  • 35.2.5 Handover
  • 35.3 Assessing the Paediatric Trauma Patient aka ‘The Primary Survey’
  • 35.3.1 Catastrophic Haemorrhage
  • 35.3.2 Airway Issues
  • 35.3.3 Breathing (Thoracic Injury)
  • 35.3.3.1 Blunt Injuries
  • 35.3.4 Penetrating Injuries
  • 35.3.4.1 Thoracotomy
  • 35.3.5 Circulation (Haemorrhage)
  • 35.3.5.1 Challenge of the Bleeding Child
  • 35.3.5.2 ‘One on the Floor and Four More’
  • 35.3.5.3 Blood Products or Crystalloid
  • 35.3.5.4 ‘Code Red’ Care in Children
  • 35.3.6 Disability (Traumatic Brain Injury and Spinal Injury)
  • 35.3.6.1 Potential Spinal Injury and Immobilisation
  • 35.3.6.2 Confirmed Spinal Injury
  • 35.3.7 Exposure
  • 35.4 Decision-Making After the Primary Survey
  • 35.5 Burns and Blasts
  • 35.5.1 Electric Burns
  • 35.5.2 Blast Injuries
  • 35.6 Traumatic Cardiac Arrest
  • 35.6.1 Which Children Survive TCA?
  • 35.6.2 Logistics of Running the Arrest
  • 35.6.3 H: Addressing Hypovolaemia
  • 35.6.4 O: Addressing Hypoxia
  • 35.6.5 T: Addressing Tension Pathology
  • 35.6.6 Non Accidental Injury or Suspected Physical Abuse
  • 35.6.7 Rational Prioritisation
  • 35.6.8 Recognition of Futility
  • 35.6.9 Debrief
  • 35.7 Traumatic Asphyxia—Hanging and Drowning
  • 35.7.1 Hanging and Near Hanging
  • 35.7.2 Drowning
  • 35.8 Deterioration in PICU
  • 36. Traumatic Brain Injury
  • 36.1 Introduction
  • 36.2 Basic Concepts
  • 36.2.1 Cerebral Blood Flow, Perfusion Pressure, Autoregulation
  • 36.2.1.1 ICP Waveforms
  • 36.2.1.2 The Pressure-Time Burden
  • 36.2.2 Concepts Behind Brain Injury
  • 36.2.2.1 Primary Brain Injury
  • 36.2.2.2 Secondary Injury
  • Ischaemia
  • Excitotoxicity and Inflammation
  • Oxidative Stress
  • Cortical Spreading Depolarisation
  • Impaired Glymphatic Drainage
  • Energy Failure
  • 36.2.2.3 Herniation Syndromes
  • 36.3 Management
  • 36.3.1 Pre-Hospital Management
  • 36.3.2 Emergency Room
  • 36.3.3 PICU Management
  • 36.3.3.1 ICP Monitoring
  • 36.3.4 Post-TBI Neuroprotection Bundle
  • 36.3.4.1 Managing CPP
  • 36.3.5 Multimodal Neuromonitoring
  • 36.3.5.1 Quantitative EEG
  • 36.3.5.2 Near-Infrared Spectroscopy (NIRS)
  • 36.3.5.3 PbtO2 (Brain Tissue Oxygen Monitoring)
  • 36.3.5.4 Transcranial Doppler (TCD)
  • 36.3.5.5 Pressure Reactivity Index (PRx)
  • 36.3.5.6 ICP Treatment Thresholds
  • 36.3.6 ICP Reduction Strategies
  • 36.3.6.1 Hyperosmolar Therapy
  • 36.3.6.2 CSF Drainage
  • 36.3.6.3 Tier 2 Therapies
  • 36.3.6.4 Hyperventilation
  • 36.3.6.5 Hypothermia
  • 36.3.6.6 Barbiturate Infusion
  • 36.3.6.7 Decompressive Craniectomy
  • 36.3.7 The Lund Concept
  • 36.4 Rehabilitation and Outcomes
  • 36.4.1 Step-Down from PICU
  • 36.4.2 Outcomes and Prognostication
  • 36.4.3 Biomarkers
  • 36.4.4 Late Effects of Paediatric TBI
  • 36.5 Clinical Trials in Paediatric TBI
  • 37. Monitoring the Brain
  • 37.1 Introduction
  • 37.2 Neuromonitoring Techniques
  • 37.2.1 EEG
  • 37.2.2 Imaging
  • 37.2.3 Increased Intracranial Pressure (ICP) and Advanced Cerebral Monitoring
  • 37.2.4 Brain Oxygenation and Metabolism
  • 37.2.5 Transcranial Doppler (TCD)
  • 37.2.6 Key Points
  • 38. Management of Seizures and Refractory Status Epilepticus in Critically Ill Children
  • 38.1 Introduction
  • 38.1.1 Definitions
  • 38.1.2 Epidemiology: Incidence of Each Including Morbidity and Mortality
  • 38.1.3 Aetiology
  • 38.1.4 Pathophysiology
  • 38.2 Investigations and Diagnosis
  • 38.3 Treatment
  • 38.3.1 Stabilization
  • 38.3.2 First-Line Therapy
  • 38.3.3 Second-Line Therapy
  • 38.3.4 Anaesthetic Drugs: Refractory and Super Refractory SE
  • 38.3.4.1 Midazolam
  • 38.3.4.2 Thiopental/Pentobarbital
  • 38.3.4.3 Propofol
  • 38.3.4.4 Ketamine
  • 38.3.5 Special Considerations for Seizures in Critically Ill Children with Acute Neurological Conditions
  • 38.3.5.1 Post-traumatic Seizures and Status Epilepticus
  • 38.3.5.2 Post-anoxic Seizures
  • 38.3.6 Other Agents to Consider
  • 38.3.6.1 Anti-Seizure Medications
  • 38.3.6.2 Pyridoxine, Pyridoxal-5-Phosphate, Folinic Acid, and Biotin
  • 38.3.6.3 Steroids and Immunotherapy
  • 38.3.6.4 Ketogenic Diet
  • 38.3.6.5 Epilepsy Surgery
  • X: Hematological Issues in PICU
  • 39. Haemoglobinopathies and Haemostatic Disorders in the PICU
  • 39.1 Introduction
  • 39.2 Sickle Cell Disease
  • 39.2.1 Multi-System Organ Failure
  • 39.2.2 Acute Chest Syndrome
  • 39.2.3 Stroke
  • 39.2.4 Transfusions for Sickle Cell Disease
  • 39.3 Haemophilia
  • 39.3.1 Haemophilia A
  • 39.3.2 Haemophilia B
  • 39.4 Thalassaemia
  • 39.5 Catastrophic Antiphospholipid Syndrome (CAPS)
  • 39.6 Immune Thrombocytopenia
  • 39.7 Thrombotic Thrombocytopenic Purpura
  • 39.8 Disseminated Intravascular Coagulation
  • 40. Transfusion Medicine in the Pediatric Intensive Care Unit
  • 40.1 Introduction
  • 40.2 Red Blood Cells
  • 40.2.1 Anemia and O2 Delivery
  • 40.2.2 When Should We Transfuse?
  • 40.3 Plasma
  • 40.3.1 When Should We Transfuse?
  • 40.4 Platelets
  • 40.4.1 When Should We Transfuse?
  • 40.4.2 When Should We Not Transfuse?
  • 40.5 Blood Product Modifications
  • 40.5.1 Leukoreduction
  • 40.5.2 Irradiated Blood Products
  • 40.5.3 Pathogen Reduction
  • 40.6 Transfusion Reactions and Complications
  • 40.6.1 Early-Onset Reactions
  • 40.6.2 Delayed Transfusion Reactions
  • 40.6.3 Infectious Risks
  • XI: Specific Situations
  • 41. Sepsis and Septic Shock
  • 41.1 Introduction
  • 41.2 Evolving Definitions of Sepsis
  • 41.3 Aetiology
  • 41.4 Identifying the Child with Sepsis
  • 41.5 Pathophysiology
  • 41.6 Antimicrobial Therapy
  • 41.7 Vascular Access and Fluid Therapy
  • 41.8 Vasoactive Agents
  • 41.9 Corticosteroids
  • 41.10 Respiratory Support
  • 41.11 Monitoring the Child with Septic Shock
  • 41.12 Electrolytes and Metabolites
  • 41.13 Blood and Blood Product Transfusion
  • 41.14 Refractory Septic Shock
  • 41.15 Renal Replacement Therapy
  • 41.16 Therapeutic Plasma Exchange/Plasmapheresis
  • 41.17 Immunoglobulin Therapy
  • 41.18 Extracorporeal Membrane Oxygenation (ECMO)
  • 41.19 Conclusion
  • 42. Hemorrhagic Shock in Children
  • 42.1 Introduction
  • 42.2 Diagnosis of Hemorrhagic Shock
  • 42.3 Management of Hemorrhagic Shock in Children
  • 42.3.1 Context of Damage Control Resuscitation in Children
  • 42.3.2 Stop the Bleed
  • 42.3.3 Rapid Rewarming
  • 42.3.4 Permissive Hypotension in Children
  • 42.3.5 Fluids and Drugs Administration
  • 42.4 Damage Control Hemostatic
  • 42.5 Damage Control Surgery (DCS)
  • 42.6 Assessment of the Effectiveness of Treatment
  • 43. Abdominal Trauma
  • 43.1 Introduction
  • 43.2 Spleen
  • 43.2.1 Frequency
  • 43.2.2 Trauma Mechanism
  • 43.2.3 Diagnosis
  • 43.2.3.1 Clinical
  • 43.2.3.2 Imaging and Biology
  • 43.2.3.3 Grade Classification
  • 43.2.4 Treatment
  • 43.2.4.1 Non-operative Management
  • 43.2.4.2 Arterial Embolization
  • 43.2.4.3 Surgery
  • 43.2.5 Monitoring
  • 43.2.6 Follow-Up
  • 43.2.6.1 Complications
  • 43.2.6.2 Control Imaging
  • 43.2.6.3 Vaccination
  • 43.3 Liver
  • 43.3.1 Frequency
  • 43.3.2 Trauma Mechanism
  • 43.3.3 Diagnosis
  • 43.3.3.1 Clinical
  • 43.3.3.2 Imaging and Biology
  • 43.3.3.3 Grade Classification
  • 43.3.4 Treatment
  • 43.3.4.1 Non-operative Management
  • 43.3.4.2 Arterial Embolization
  • 43.3.4.3 Surgery
  • 43.3.5 Monitoring
  • 43.3.6 Complications
  • 43.3.6.1 Vascular Complications
  • 43.3.6.2 Biliary Peritonitis
  • 43.3.6.3 Bilioma
  • 43.3.7 Follow-Up
  • 43.3.7.1 Control Imaging
  • 43.4 Kidney
  • 43.4.1 Frequency
  • 43.4.2 Trauma Mechanism
  • 43.4.3 Diagnosis
  • 43.4.3.1 Clinical
  • 43.4.3.2 Biology and Radiology
  • 43.4.4 Treatment
  • 43.4.4.1 Non-operative Management
  • 43.4.4.2 Surgical Treatment
  • 43.4.5 Complications
  • 43.5 Pancreas
  • 43.5.1 Frequency
  • 43.5.2 Trauma Mechanism
  • 43.5.3 Diagnosis
  • 43.5.3.1 Clinical
  • 43.5.3.2 Radiological and Biological
  • 43.5.4 Treatment
  • 43.5.4.1 Non-operative Management
  • 43.5.4.2 Surgery
  • 43.5.5 Follow-Up
  • 44. Immunosuppressed Patients
  • 44.1 Introduction
  • 44.2 Primary Immunodeficiency (PID)
  • 44.3 Hemophagocytic Lymphohistiocytosis (HLH)
  • 44.3.1 Clinical Diagnosis
  • 44.3.2 Treatment
  • 44.4 Hematopoietic Stem Cell Transplantation (HSCT)
  • 44.4.1 General Considerations
  • Box 44.1: Key Information Upon Admission of a HSCT Patient on PICU
  • 44.4.2 Approach to the HSCT Patient with Organ Failure
  • 44.4.2.1 Respiratory Failure
  • 44.4.2.2 Acute Kidney Injury (AKI)
  • 44.4.2.3 Acute Encephalopathy
  • Box 44.2: Immune Reconstitution and Infections
  • Box 44.3: Early HSCT-Related Morbidity
  • Acute Graft-Versus-Host Disease (aGVHD)
  • Veno-Occlusive Disease (VOD)
  • Transplant-Associated Thrombotic MicroAngiopathy (TA-TMA)
  • 45. Paediatric Onco-Critical Care
  • 45.1 Introduction
  • 45.2 Tumour Lysis Syndrome
  • 45.2.1 Pathophysiology
  • 45.2.2 Diagnosis
  • 45.2.3 Treatment
  • 45.3 Hyperleukocytosis
  • 45.3.1 Pathophysiology
  • 45.3.2 Diagnosis
  • 45.3.3 Treatment
  • 45.4 Mediastinal Tumours
  • 45.4.1 Symptoms
  • 45.4.2 Treatment
  • 45.5 Posterior Reversible Encephalopathy Syndrome (PRES)
  • 45.5.1 Pathophysiology
  • 45.5.2 Diagnosis
  • 45.5.3 Treatment
  • 45.6 Intracranial Hypertension
  • 45.6.1 Pathophysiology
  • 45.6.2 Symptoms and Clinical Signs of Intracranial Hypertension
  • 45.6.3 Diagnostics
  • 45.6.4 Therapy
  • 45.6.4.1 Conservative Treatment Strategies
  • 45.6.4.2 Surgical Treatment Strategies
  • 45.7 Sepsis and Non-infectious Inflammatory Conditions
  • 45.7.1 Sepsis Definition
  • 45.7.2 Micro-organisms and Antibiotics
  • 45.7.3 Septic Shock Management and Organ Support
  • 45.7.4 Special Circumstances
  • 46. End-of-Life Nursing for Children and Families in ICU
  • 46.1 Introduction
  • 46.2 Experiences and Care Needs of Families in the PICU
  • 46.3 When a Child Dies in the PICU
  • 46.3.1 Family Experiences of End-of-Life Care in the PICU
  • 46.3.2 Supporting Families When Their Child Is Dying: Some Practical Suggestions
  • 46.4 After a Child Has Died in the ICU
  • 46.4.1 Family Experiences of Post-death and Bereavement Care in the ICU
  • 46.4.2 Supporting Families After a Child’s Death: Some Practical Suggestions
  • 47. Paediatric Organ Donation
  • 47.1 Introduction
  • 47.1.1 Importance of Deceased Organ Donation
  • 47.2 Paediatric Perspective
  • 47.3 Ethics of Deceased Donation
  • 47.3.1 What Makes Deceased Donation Ethical
  • 47.3.1.1 Implicit or Presumed Consent
  • 47.3.1.2 Explicit Consent
  • 47.3.2 Ethical Framework
  • 47.4 Understanding the Diagnosis of Death Using Circulatory and Neurological Criteria
  • 47.4.1 All Human Death Is Death of the Brain
  • 47.4.1.1 Somatic Criteria
  • 47.4.1.2 Circulatory Criteria
  • 47.4.1.3 Neurological Criteria
  • 47.5 How to Diagnose Death Using Circulatory Criteria
  • 47.6 How to Diagnose Death Using Neurological Criteria [13]
  • 47.7 UK Procedure for Neurological Determination of Death [13]
  • 47.7.1 Neurological Determination of Death in the Neonate
  • 47.8 Donation Processes
  • 47.8.1 UK Example
  • 47.8.2 Donation After Circulatory (Cardiac) Death DCD
  • 47.8.2.1 Warm Ischaemic Injury in DCD
  • 47.8.3 Donation After Neurological Determination of Death DBD
  • 47.8.4 Donor Identification and Referral
  • 47.8.5 Organ Retrieval
  • 47.9 International Perspectives
  • 48. Toxicology in Pediatric ICU
  • 48.1 Introduction
  • 48.2 Clinical Presentation
  • 48.3 Initial Management
  • 48.4 Investigations
  • 48.5 Criteria for PICU Admission
  • 48.6 Specific Management
  • 48.6.1 Whole Bowel Irrigation
  • 48.6.2 Multi-dose Activated Charcoal
  • 48.6.3 Urine Alkalinization
  • 48.6.4 Extracorporeal Removal
  • 48.6.5 Antidote Therapy
  • 48.6.6 Lipid Emulsion Therapy
  • 48.7 Ancillary Support and Prevention
  • Summary
  • Case Study
  • Presenting Complaints and History
  • Physical Examination
  • Initial Treatment
  • Details of Substance Ingested and Past Medical History
  • Diagnostic Testing
  • Hospital Course
  • Ancillary Tests
  • 49. Burns in Children
  • 49.1 Introduction
  • 49.2 Resuscitation and Stabilization
  • 49.2.1 Airway and Lower Respiratory Tract
  • 49.2.2 Fluid Resuscitation After Thermal Injuries
  • 49.2.3 Transport to a Burn Service
  • 49.2.4 Ongoing Management: Surgical
  • 49.2.5 Ongoing Management: Medical
  • 49.2.5.1 Cardiovascular
  • 49.2.5.2 Hypermetabolic Response
  • 49.2.5.3 Nutritional Support and Gastro-Intestinal Support
  • 49.2.5.4 Infection and Sepsis
  • 49.2.5.5 Lines and Thromboprophylaxis
  • 49.2.5.6 Sedation and Pain Management
  • 49.3 Conclusion
  • Appendix
  • 50. Surgical Neonates in PICU
  • 50.1 Introduction
  • 50.2 Preoperative Care of Surgical Neonates
  • 50.3 Common Surgical Conditions
  • 50.3.1 Tracheo-Oesophageal Fistula and Oesophageal Atresia
  • 50.3.2 Congenital Diaphragmatic Hernia
  • 50.3.3 Abdominal Wall Defects
  • 50.3.3.1 Exomphalos
  • 50.3.3.2 Gastroschisis
  • 50.3.4 Intestinal Obstruction
  • 50.3.5 Necrotising Enterocolitis
  • 50.4 Postoperative Care of Surgical Neonates
  • 51. Transport of the Critically Ill Child
  • 51.1 Introduction
  • 51.2 Referral to a PCCT
  • Box 51.1: Suggested Structure for the Initial Referral Call
  • 51.3 The Transport Process
  • 51.3.1 Staffing and Equipment
  • 51.3.2 Handover at Referring Centre
  • 51.3.3 Patient Stabilisation
  • Box 51.2: Suggested Emergency Equipment and Drugs for Transport
  • 51.3.3.1 Airway
  • 51.3.3.2 Breathing
  • 51.3.3.3 Circulation
  • 51.3.3.4 Disability
  • 51.3.3.5 Exposure
  • 51.3.4 Packaging for Transport
  • Box 51.3: Oxygen Cylinder Capacities for Commonly Used Cylinder Types [14]
  • 51.3.5 The Transport Phase
  • 51.3.6 Handover at Receiving Centre
  • 51.4 Time-Critical Transfers
  • 51.5 Air Transport
  • 51.6 Safety and Clinical Governance
  • 52. Analgosedation in the Pediatric Intensive Care Unit
  • 52.1 Introduction
  • 52.2 Two Basic Concepts: Pain and Distress
  • 52.2.1 Definition of Pain
  • 52.2.2 Developmental Aspects of Pain
  • 52.2.3 The Conceptual Model of Pain
  • 52.2.4 Incidence of Pain
  • 52.3 Pain Assessment
  • 52.4 Treatment Interventions
  • 52.4.1 Non-pharmacological Interventions
  • 52.4.2 Pharmacological Interventions
  • 52.5 Conclusion
  • Supplementary Data
  • Specific Pharmacology Data
  • Analgesic Drugs
  • Opioids
  • Non-opioids
  • Sedative Drugs
  • Benzodiazepines
  • Alfa (α-2)-Adrenergic Agonists
  • Barbiturates
  • Volatile Anesthetics
  • Local Anesthetics
  • XII: Vital Support
  • 53. Clinical Pharmacology in the Paediatric Intensive Care Unit
  • 53.1 Introduction
  • 53.2 General Aspects of Clinical Pharmacology
  • 53.2.1 PK Processes: Its Language and Parameters
  • 53.2.2 Dose and Dosing Interval
  • 53.2.3 Targeted Pharmacotherapy
  • 53.2.4 Pharmacokinetic Models
  • 53.2.5 General Factors
  • 53.3 Specific Aspects of Clinical Pharmacology
  • 53.3.1 Maturational Factors
  • 53.3.2 Non-maturational Factors
  • 53.4 Evidence-based Pharmacotherapy
  • 53.4.1 Rational Use of Drugs
  • 53.4.2 Therapeutic Drug Monitoring
  • 53.4.3 Specific Drugs
  • 53.5 Conclusion
  • Appendix
  • 54. Continuous Kidney Replacement Therapy in Children
  • 54.1 Introduction
  • 54.2 Early Development
  • 54.3 Mechanisms of Solute Removal in KRT
  • 54.4 Modalities of KRT
  • 54.5 Indications of KRT
  • 54.6 Timing of Initiation of KRT
  • 54.7 CKRT Devices–CKRT Devices
  • 54.8 CKRT Prescription (◘ Table 54.3)
  • 54.9 Future Directions
  • 54.10 Conclusions
  • 55. Role of Dietitian and Nutrition in Paediatric Critical Care
  • 55.1 Introduction
  • 55.2 Organising Nutrition Care
  • 55.3 Anthropometry (A)
  • 55.3.1 Quality Assurance Framework for the Measurement of Anthropometry
  • 55.4 Biochemistry (B)
  • 55.4.1 Refeeding Syndrome
  • 55.5 Clinical (C)
  • 55.6 Dietary (D)
  • 55.7 Evaluation (E)
  • 56. Psychology
  • 56.1 Introduction
  • 56.2 Psychological Care of the Child
  • Box 56.1. Post-traumatic Stress Disorder (ICD-11 Code 6B40)
  • 56.3 Supporting Parents
  • Box 56.2. Psychological First Aid [18]
  • Box 56.3. Useful Online Resources
  • 57. Ethics in Paediatric and Neonatal ICU
  • 57.1 Introduction
  • 57.2 Traditional Moral Theories
  • 57.3 Ethics in Modern PICU
  • 57.4 Death
  • 57.5 Moral Injury
  • 57.6 Pandemics
  • 57.7 Consent
  • 57.8 Research
  • 57.9 Second Opinions
  • 57.10 Ethics Support
  • 58. Chaplains and Faith Support
  • 58.1 Introduction
  • 58.2 The Taxonomy
  • 58.3 Setting
  • 58.3.1 Intended Effect
  • 58.3.2 Method
  • 58.3.3 Intervention
  • 58.4 Who Carries Out This Work?
  • 58.5 How Does the Work Happen?
  • 58.6 What Are the Processes?
  • 58.7 Distinctions
  • 58.8 Themes
  • 58.9 Outcomes
  • 58.10 Resourcing and Training
  • 58.11 Conclusion
  • XIII: Looking After People
  • 59. Caring and Listening to Families in the ICU
  • 59.1 Introduction
  • 59.2 Family-Centred Care
  • 59.2.1 The Parental Impact of Paediatric Intensive Care
  • 59.2.2 Paediatric Intensive Care and Its Effect on Siblings
  • 59.3 PIC Survivorship: Morbidity
  • 59.4 Supporting the Parental Role
  • 59.4.1 Visiting
  • 59.4.2 Delivering Care
  • 59.4.3 Ward Rounds, Decision-Making and Communication
  • 59.4.4 Transitions
  • 59.5 The Multidisciplinary Team
  • 59.5.1 Family Liaison Service
  • 59.5.2 Psychology
  • 59.5.3 Religious and Spiritual Support
  • 59.5.4 Play Specialists
  • 59.6 Care of the Family at the End of Life
  • 59.7 When Death is Expected or Imminent
  • 59.8 Resuscitation
  • 59.9 After Death
  • 59.10 Bereavement Services
  • 59.11 Mediation, Feedback and Liaison
  • 59.12 Peer Support Services
  • 59.13 Practical Matters
  • Summary
  • 60. Care of the Critical Care Team
  • 60.1 Introduction
  • 60.2 Burnout
  • 60.3 Post-Traumatic Stress
  • 60.4 Moral Distress
  • 60.5 Special Situations
  • 60.6 Self-Care and Organisational Level Interventions
  • Box 60.1. Burnout
  • Box 60.2. Post-traumatic Stress Disorder (ICD-11 code 6B40)
  • Box 60.3. Moral Distress
  • Box 60.4. Useful Online Resources
  • 61. Management of Older Children in the ICU
  • 61.1 Introduction
  • 61.2 Definitions
  • Box 61.1 Definitions Pertinent to Adolescent Medicine
  • 61.3 Diagnostic Spectrum
  • Box 61.2 The 6 Ps
  • 61.4 Practical Issues
  • 61.4.1 Physical Differences
  • 61.4.2 Experiences on ICU
  • 61.5 Privacy
  • 61.6 Personal Life
  • Box 61.3 HEADSSS Risk Assessment
  • 61.7 Puberty
  • 61.8 Prophylaxis
  • Box 61.4 Risk Factors for VTE
  • 61.9 Permission
  • 61.9.1 Communication
  • 61.9.2 Consent
  • 61.9.3 Confidentiality
  • XIV: Where Do Critically Ill Children Go?
  • 62. Outcomes in PICU
  • 62.1 Introduction
  • 62.2 Case Reports
  • 62.3 Physical Outcomes After Pediatric Critical Illness
  • 62.4 Psychological Outcomes After Pediatric Critical Illness
  • 62.4.1 The “New Normal”
  • 62.4.2 Quality of Life
  • 62.5 Post-traumatic Stress
  • 62.6 Neurocognitive Outcome
  • 62.7 Predictors: What Affects Outcome After a PICU Admission?
  • 62.8 Challenges and Future Directions for Follow-Up
  • XV: Research Needed in the ICU
  • 63. What Do We Need to Find Out?
  • 63.1 Introduction
  • 63.2 So, What Do We Need to Find Out?
  • Case Study
  • 63.2.1 Consider Now: How Much of the Therapies, Practices, and Policies Above Do We Have Clear Evidence For?
  • 63.2.1.1 Why We Need to Question the Evidence for Our Routine and Historical Practices
  • XVI: Education
  • 64. Online Education
  • 64.1 Introduction
  • 64.2 What Qualifies as “Online Education”?
  • 64.3 Implementing Online Education: A Pragmatic Approach
  • 64.3.1 Problem Identification
  • 64.3.2 Needs Assessment
  • 64.3.3 Describing Goals and Objectives
  • 64.3.4 Selecting Educational Strategies
  • 64.3.5 Implementation of the Intervention
  • 64.3.6 Evaluation and Feedback
  • 64.4 Evidence for Online Medical Education
  • 64.5 Educational Features (◘ Table 64.2)
  • 65. Simulation in Pediatric Critical Care
  • 65.1 Introduction
  • 65.1.1 Challenges in Pediatric Critical Care Education
  • 65.2 Evolution of Paediatric Resuscitation Training
  • 65.2.1 History of CPR Training
  • 65.2.2 Quality CPR Training in Pediatrics
  • 65.2.3 Basic Concept of Role-Play Simulated Scenarios
  • 65.2.4 Importance of Simulation and Debriefing in CPR Training
  • 65.3 Crisis Resource Management in Pediatric Resuscitation Teams
  • 65.3.1 Leadership and Followership
  • 65.3.2 Communication
  • 65.3.3 Use of Resources
  • 65.3.4 Situational Awareness
  • 65.4 Future Perspectives
  • 65.4.1 Rapid Cycle Deliberate Practice and Repeated Encounters
  • 65.4.2 Gaming
  • 65.4.3 Boot Camp
  • 65.4.4 Coaching, Codes and Mock Codes
  • 65.4.5 Telesimulation